Aurinia Pharmaceuticals Q1 2024 Earnings Report $8.04 -0.25 (-3.02%) As of 04:00 PM Eastern Earnings HistoryForecast Aurinia Pharmaceuticals EPS ResultsActual EPS-$0.03Consensus EPS -$0.17Beat/MissBeat by +$0.14One Year Ago EPSN/AAurinia Pharmaceuticals Revenue ResultsActual Revenue$50.30 millionExpected Revenue$46.30 millionBeat/MissBeat by +$4.00 millionYoY Revenue GrowthN/AAurinia Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/2/2024TimeN/AConference Call ResourcesPress ReleaseAUPH Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Aurinia Pharmaceuticals Earnings HeadlinesAurinia Pharmaceuticals (NASDAQ:AUPH) Raised to Strong-Buy at StockNews.comMarch 28 at 3:39 AM | americanbankingnews.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comThe Greatest "Income Opportunity" of 2025?It has been a wild couple of months so far. And not just in the markets. In our everyday lives. For me, it's highlighted the importance of investment income you can count on…even when life becomes unpredictable. Which is why I've put together this urgent presentation.March 31, 2025 | Behind the Markets (Ad)Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting PointMarch 6, 2025 | finance.yahoo.comResults: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMarch 2, 2025 | uk.finance.yahoo.com1AUPH : Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit,...March 1, 2025 | benzinga.comSee More Aurinia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email. Email Address About Aurinia PharmaceuticalsAurinia Pharmaceuticals (NASDAQ:AUPH), a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.View Aurinia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
